Celldex Therapeutics, Inc.

During the next twelve months and beyond, the Company may take further steps to raise additional capital to meet its long-term liquidity needs including, but not limited to, one or more of the following: the licensing of drug candidates with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Additional equity financings may be dilutive to the Company s stockholders; debt financings, if available, may involve significant cash payment obligations and covenants that restrict the Company s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company s economic potential from products under development.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

8 Table of Contents (5) Marketable Securities The following is a summary of marketable debt securities, classified as available-for-sale: Amortized Gross Unrealized Gross Unrealized Fair Cost Gains Losses Value (In thousands) June 30, 2026 Marketable securities U.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

government and municipal obligations $ 193,628 $ 606 $ $ 194,234 Corporate debt securities Maturing in one year or less $ 257,064 $ 373 $ $ 257,437 Maturing after one year through three years 37,980 55 ( 4 ) 38,031 Total corporate debt securities $ 295,044 $ 428 $ ( 4 ) $ 295,468 Total marketable securities $ 488,672 $ 1,034 $ ( 4 ) $ 489,702 The Company holds investment-grade marketable securities.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Celldex team is working diligently to bring this important medicine to patients and we remain focused on executing across our Phase 3 program in CSU, which is on track and expected to be fully enrolled next summer.

SEC original ↗Celldex Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Additional equity financings may be dilutive to the Company s stockholders; debt financings, if available, may involve significant cash payment obligations and covenants that restrict the Company s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company s economic potential from products under development.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Our next generation bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Development is focused on emerging, important pathways controlling inflammatory diseases.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Our strategy is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

On August 18, 2020, Celldex filed a Verified Complaint in the Court of Chancery of the State of Delaware against SRS (acting in its capacity as the representative of the former stockholders of Kolltan pursuant to the Merger Agreement) seeking declaratory relief with respect to the rights and obligations of the parties relating to certain contingent milestone payments under the Merger Agreement relating to the discontinued CDX-0158 program (the Litigation ).

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

On July 15, 2022, the Company entered into a definitive settlement agreement between the Company and SRS (the Settlement Agreement ) and the Company and SRS jointly filed a Stipulation of Dismissal with prejudice relating to the Litigation on July 19, 2022.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Under the Settlement Agreement, each of the Company and SRS provided broad mutual releases of all claims relating to or arising out of the Merger Agreement, including without limitation, all claims brought in the Litigation or that could have been brought in the Litigation.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

A future milestone payment related to the barzolvolimab program, which was subject to the Litigation, will be recorded when and if payment becomes probable and reasonably estimable in accordance with the loss contingency model under ASC 450.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

18 Table of Contents The expenditures that will be necessary to execute our business plan are subject to numerous uncertainties.

SEC original ↗Celldex Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026